The Turkish Journal of Pediatrics 2021 , Vol 63 , Num 5
Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors
Seher Şener 1 ,Aylar Poyraz 2 ,Arzu Okur 1 ,Faruk Güçlü Pınarlı 1 ,Ceyda Karadeniz 1
1 Departments of Pediatric Oncology, Gazi University Faculty of Medicine Hospital, Ankara, Turkey
2 Departments of Pathology, Gazi University Faculty of Medicine Hospital, Ankara, Turkey
DOI : 10.24953/turkjped.2021.05.004 Background. Programmed death 1 (PD-1) is a co-receptor which is located at the surface of cells like natural killer, monocytes, T and B cells. It has two ligands including programmed death ligand-1 (PD-L1) and ligand-2 (PD-L2). T cell functions are inhibited by activation of PD-1/PD-L1 pathway and this pathway is used by viruses and some tumor cells in order to escape from immune eradication. In our study we evaluated PD-L1 expression in the tissue specimens of patients with Wilms tumor, neuroblastoma and other renal tumors.

Methods. Totally 60 patients who were followed up at Gazi University Hospital with the diagnosis of neuroblastoma, Wilms tumor and other renal tumors were included. PD-L1 expression was examined in tumor samples of the patients.

Results. Positive staining with PD-L1 was detected only in two male patients. Both of them had neuroblastoma and advanced stage disease. None of the patients with Wilms tumor and other renal tumors had positive PD-L1 staining.

Conclusions. Unlike adult tumors, PD-L1 expression is not common in childhood tumors due to differences in immune system between children and adults. Further studies are needed to establish the importance and effects of PD-1/PD-L1 pathway in pediatric tumors. Keywords : programmed death-1, programmed death ligand-1, programmed death ligand-2, neuroblastoma, childhood renal tumors

Copyright © 2016